• Aliases: KW-0761; AMG-761
    • A recombinant, humanized monoclonal mAb of the Ig G subclass 1 kappa (IgG1κ) isotype that targets CCR4-expressing cells; it may induce ADCC against CCR4-positive T cells
    • Approved in Japan for relapsed or refractory CCR4-positive PTCL and CTCL and chemotherapy-native CCR4-positive adult T-cell leukemia-lymphoma.
    • FDA granted Breakthrough Therapy Designation status for the treatment of mycosis fungoides and Sézary syndrome.
    • Recommended dose: 1 mg/kg IV Q week for 8 doses (approved in Japan)
    • Half-life: 17.5 days
    • Common side effects: Infusion-related side effects such as fevers, chills, rigors, neutropenia, transaminitis, thrombocytopenia
    Other topics in Targeted and Immunotherapy Agents